New Business Models For Personalized Medicine: Look To The Stars?
This article was originally published in The Pink Sheet Daily
Executive Summary
‘How to’ on small clinical trials written for NASA may be required reading for drug developers.
You may also be interested in...
M&A Fireworks: Shire Buys Jerini For €328 Million
Jerini secures a hefty payout, despite FDA deeming HAE candidate Firazyr “not approvable.”
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.